trending Market Intelligence /marketintelligence/en/news-insights/trending/oCMqT-Z0UFq8jRqyXROeZg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

FibroGen appoints Lilly veteran as CEO

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


FibroGen appoints Lilly veteran as CEO

FibroGen Inc. said its board appointed Enrique Conterno as CEO, replacing Jim Schoeneck.

Schoeneck became FibroGen's interim CEO after Thomas Neff, the company's chairman, founder and CEO, died in August 2019.

Conterno previously was the senior vice president at Eli Lilly and Co. and retired from the pharmaceutical giant at the end of 2019.

San Francisco-based FibroGen discovers, develops and commercializes treatments for chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis and pancreatic cancer.